Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.
Morningstar29d
Agios’ Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint
– ACTIVATE-Kids is the First Study to Demonstrate Efficacy of an Oral Therapy for Children with PK Deficiency Who Are Not Regularly Transfused – – Safety Results Consistent with Safety ...
Business Insider1mon
Travere Therapeutics to Submit sNDA for FILSPARI® (sparsentan) in FSGS
Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25 If approved, FILSPARI could be the first and only approved medicine ...
Travere Therapeutics to Submit sNDA for FILSPARI® (sparsentan) in FSGS
Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.
Frontiers1mon
A review of the genomics of neonatal abstinence syndrome
Neonatal abstinence syndrome (NAS) is a constellation of signs of withdrawal occurring after birth following in utero exposure to licit or illicit opioids. Despite significant research and public ...
Frontiers1mon
Case report: Non-response to fluoxetine in a homozygous 5-HTTLPR S-allele carrier of the serotonin transporter gene
Major depressive disorder (MDD) is a common condition that imposes a high disease burden on the individual patient (1). However, not only the affected patients, but also the healthcare system and ...
Finanznachrichten2mon
Travere Therapeutics, Inc.: Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
Company to submit sNDA around the end of 1Q 2025 seeking traditional approval of FILSPARI® (sparsentan) for FSGS Net product sales of FILSPARI totaled $50 million in 4Q 2024; $132 million for full ...